Liquidia to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
Liquidia Technologies (Nasdaq: LQDA) will have its CEO, Neal Fowler, present a company overview at the 2020 Wedbush PacGrow Healthcare Virtual Conference on August 11, 2020, at 10:20 AM ET. The event will highlight Liquidia's focus on developing novel biopharmaceutical products using its proprietary PRINT® technology, aimed at enhancing patient outcomes. Liquidia is currently developing two primary candidates: LIQ861 for pulmonary arterial hypertension and LIQ865 for postoperative pain. A live audio webcast will be available for attendees.
- None.
- None.
RESEARCH TRIANGLE PARK, N.C., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products utilizing its proprietary PRINT® technology, today announced that Neal Fowler, Chief Executive Officer of Liquidia, will present a company overview at the 2020 Wedbush PacGrow Healthcare Virtual Conference on Tuesday, August 11, 2020 at 10:20am Eastern time.
A link to the live audio webcast and replay of the presentation will be available on the Events & Presentations page of the Company’s corporate website, and will be archived for a minimum of 90 days.
About Liquidia
Liquidia is a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINT® technology to transform the lives of patients. PRINT is a particle engineering platform that enables precise production of uniform drug particles designed to improve the safety, efficacy and performance of a wide range of therapies. Currently, Liquidia is focused on the development of two product candidates for which it holds worldwide commercial rights: LIQ861 for the treatment of pulmonary arterial hypertension (PAH) and LIQ865 for the treatment of local post-operative pain. Liquidia is headquartered in Research Triangle Park, NC. For more information, please visit www.liquidia.com.
Contact Information
Investor Relations:
Jason Adair
Vice President, Corporate Development and Strategy
919.328.4400
jason.adair@liquidia.com
FAQ
What is Liquidia Technologies' presentation date at the 2020 Wedbush PacGrow Healthcare Virtual Conference?
Who is presenting for Liquidia Technologies at the healthcare conference?
What technologies does Liquidia utilize for its drug development?
What are the main product candidates being developed by Liquidia?
Where can I find the live audio webcast of Liquidia’s presentation?
